Literature DB >> 22425694

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Chikako Nakano1, Takayuki Hamano, Naohiko Fujii, Yoshitsugu Obi, Isao Matsui, Kodo Tomida, Satoshi Mikami, Kazunori Inoue, Akihiro Shimomura, Yasuyuki Nagasawa, Noriyuki Okada, Yoshiharu Tsubakihara, Hiromi Rakugi, Yoshitaka Isaka.   

Abstract

PURPOSE: Low 25-hydroxyvitamin D (25D), increased levels of fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and alkaline phosphatase (ALP) were reported to be risk factors for mortality in chronic kidney disease (CKD). However, the independent associations of these factors with cardiovascular disease (CVD), the leading cause of death among CKD patients, remain unclear. Our purpose was to identify which of these factors predict incident CVD in CKD.
METHODS: In this prospective cohort study, we enrolled 738 predialysis outpatients in the two nephrology departments. We employed Cox proportional hazards analyses to elucidate predictors of the endpoint, defined as fatal or non-fatal cardiovascular event requiring hospitalization. Multiple imputation was performed for missing values.
RESULTS: Mean estimated glomerular filtration rate (eGFR) was 35 mL/min/1.73 m(2). During a median duration of 4.4 years, 86 patients developed the endpoint, of whom 62 patients achieved it before the initiation of dialysis. Multivariable analyses revealed that high serum intact FGF23 levels predicted the outcome preceding dialysis initiation (hazard ratio (HR) per lnFGF23 (SD), 1.64 (1.27-2.30)), while 25D, PTH, and bone-specific ALP did not. Adding FGF23 to the conventional model of age, sex, diabetes, prior CVD, pulse pressure, and eGFR, led to a net reclassification improvement of 6.87% (P=0.04). Not censoring the patients at the start of dialysis and continuing follow-up even after dialysis, FGF23 levels did not predict the outcome (HR, 1.16 (0.91-1.48)). Complete case analyses yielded similar results.
CONCLUSIONS: Intact FGF23 levels in predialysis CKD predicted incident cardiovascular events requiring hospitalization before starting dialysis, but did not predict events during the entire follow-up period, including post dialysis initiation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425694     DOI: 10.1016/j.bone.2012.02.634

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  39 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

2.  What's new in FGF23 research?

Authors:  Seiji Fukumoto
Journal:  Bonekey Rep       Date:  2012-07-04

Review 3.  Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

4.  Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy.

Authors:  Burcu Dogan; Izzet Hakki Arikan; Derya Guler; Nursen Keles; Banu Isbilen; Ferruh Isman; Aytekin Oguz
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

5.  Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.

Authors:  Daniel Edmonston; Daniel Wojdyla; Rupal Mehta; Xuan Cai; Claudia Lora; Debbie Cohen; Raymond R Townsend; Jiang He; Alan S Go; John Kusek; Matthew R Weir; Tamara Isakova; Michael Pencina; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2019-08-21       Impact factor: 8.860

Review 6.  Coronary artery calcification in chronic kidney disease: An update.

Authors:  Tomasz Stompór
Journal:  World J Cardiol       Date:  2014-04-26

Review 7.  Clinical features of CKD-MBD in Japan: cohort studies and registry.

Authors:  Takayuki Hamano; Yusuke Sakaguchi; Naohiko Fujii; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2016-12-09       Impact factor: 2.801

8.  Dietary phosphorus restriction by a standard low-protein diet decreased serum fibroblast growth factor 23 levels in patients with early and advanced stage chronic kidney disease.

Authors:  Shunsuke Goto; Kentaro Nakai; Keiji Kono; Yuriko Yonekura; Jun Ito; Hideki Fujii; Shinichi Nishi
Journal:  Clin Exp Nephrol       Date:  2014-03-01       Impact factor: 2.801

Review 9.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

10.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.